Beating Hepatitis C: Closing Gaps in the Cascade

Carolyn Chu, MD, AAHIVS & Cristina Gruta, PharmD, AAHIVP
Clinician Consultation Center
May 21, 2018



Disclaimer

The views, opinions, and content expressed in this presentation do not necessarily reflect the views, opinions, or policies of the Center for Mental Health Services (CMHS), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Health Resources and Services Administration (HRSA), or the U.S. Department of Health and Human Services (HHS).




Disclosures

- Dr. Chu has no conflicts of interest to disclose.
- Dr. Gruta has no conflicts of interest to disclose.



Hepatitis C: What have you heard?



Why should I care about hepatitis C?

- Treatment has been revolutionized over the past few years
- Numbers of new infections are rising, despite recent attention to this important public health issue
- PBHCI/PIPBHC grantees play an extremely important role in engaging clients in prevention, screening/testing, treatment initiation, and treatment completion
- We all can help "eliminate hepatitis C"



https://www.cdc.gov/nchhstp/newsroom/2017/Hepatitis-Surveillance-Press-Release.html

Image: Clinical Care Options




Learning objectives

- Identify risk factors for HCV acquisition and transmission
- List steps in the HCV Care Continuum and why screening is vital to eliminating HCV
- Understand how to incorporate HCV screening as a part of integrative practice
- Increase awareness of how PBHCI/PIPBHC grantees can support patients living with, and/or at risk for, hepatitis C




Epidemiology update





Taking a closer look...



- Screening → linkage to HCV care → treatment cascade must work for all who are at risk
- Treatment of Person Who Inject Drugs (PWIDs) + harm reduction efforts are essential for HCV elimination efforts

California Department of Public Health. Chronic hepatitis C infections in California: cases newly reported through 2015. June 2017.








Access to prevention

2017 study: 80% of young people with HCV live > 10 miles from syringe service program (SSP)



From: Geographic Disparities in Access to Syringe Services Programs Among Young Persons With

Hepatitis C Virus Infection in the United States

Clin Infect Dis. 2017;65(3):514-517. doi:10.1093/cid/cix333

Clin Infect Dis | Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.






What increases someone's risk?

- Injection drug use (current or former); intranasal drug use
- Born between 1945-1965
- Receiving tattoos or body piercings in unregulated setting (i.e. non-sterile equipment use), such as during incarceration
- Receipt of blood, blood product, or organs before 1992; or receipt of blood/product/organ from donor with HCV
- Long-term hemodialysis
- Occupational exposures (e.g., healthcare workers & needlesticks)
- HIV infection
- Perinatal exposure (maternal HCV)
- Sharing certain household items (e.g., razor) with a person who has HCV
- Having unprotected sex with someone living with HCV (esp. MSM)



Worldwide epidemiology



Q: How can I talk with clients about their risk?


A: In much the same way you talk about their behavioral health!


- Open, non-judgmental approach
- Use plain words
- Important to use person centered language to prevent
 perpetuating bias against hepatitis C or associated risk behaviors
- Exploring someone's risk (or perception of risk) often taps into sensitive content such as sexual and substance use history
- Try to identify client's goals for the discussion pay attention to their reactions, beliefs, concerns
- Might help to start conversation with: "What have you heard about hepatitis C?"..."Can I help you with getting tested?"





















How does hepatitis C affect health?

(1) Liver inflammation

The liver:


- Breaks down medications, toxins, and nutrients
- Is important for blood clotting
- Helps store iron, some vitamins
- Helps filter blood supply
- Is the only organ that can heal!
- (2) Can also affect other organ systems ("extrahepatic" impact)








Extrahepatic manifestations: brain, mood changes











Other extrahepatic manifestations




Vasculitis, cryoglobulinemia



Lichen planus





Porphyria cutanea tarda





APLASTIC ANEMIA







Hypothyroidism



Neuropathy



Kidney disease



Goals of HCV treatment

Primary goal

Eradicate HCV infection ("cure")

Secondary goals


- Improve inflammation/scarring
- Slow down liver disease progression
- Reduce risk of liver cancer and death (end stage liver disease/cirrhosis, etc.)
- Reduce harmful impact on other organ systems
- Improve health-related quality of life
- Prevent transmission to others







Treatment can prevent onward transmission ("treatment as prevention")

Observed and modeled HCV prevalence among PWID in Australia



U.S. Hepatitis C Care Continuum: where are the gaps?










U.S. Hepatitis C Care Continuum: where are the gaps?








Screening: what it is, challenges, and best practices

- Screening involves blood testing- currently, no <u>FDA approval</u> for using saliva or other body fluids
 - Traditional laboratory testing from blood sample, <or>
 - Point-of-care ("rapid") test from fingerstick or venipuncture






← <u>Left</u>: "rapid" HCV test; ↑ <u>above</u>: dried blood spot sampling





HCV testing algorithm



antibody is recommended. For persons who are immunocompromised, testing for HCV RNA can be considered.

If someone has a positive HCV antibody, but negative/ undetectable viral load:

- "Cleared" on own without treatment
- Previously treated and cured
- "False positive"

(Antibody and viral load do **NOT** give information about severity of liver disease)



To differentiate past, resolved HCV infection from biologic false positivity for HCV antibody, testing with another HCV antibody assay can be considered. Repeat HCV RNA testing if the person tested is suspected to have had HCV exposure within the past 6 months or has clinical evidence of HCV disease, or if there is concern regarding the handling or storage of the test specimen.

Challenges to screening?

Provider/system factors

- Lack of knowledge about who is at risk
- Too many other things to address during visits
- Fragmented communication between care providers
- No one treating HCV in community

Patient factors

- Competing priorities
- Perception of low/no risk
- "Silent killer"- HCV often doesn't cause symptoms
- Lack of knowledge regarding consequences of untreated HCV
- Bias
- Mistrust of healthcare system or provider (desire for "nontraditional" screening location)






Best practices for screening

- "Reflex" testing: positive antibody automatically leads to viral load testing without requiring new sample
- Alert in electronic health record
- Screening/incentives that <u>reduce bias</u> (couple with cholesterol or diabetes screening)
- Patient <u>education</u>: flyers in center and around community
- <u>Dedicated resources and staffing</u> to facilitate <u>timely</u> <u>linkage</u> to HCV care; ideal model = on-site, co-located treatment team ("It takes a therapeutic village")











Ways to integrate screening in your practice/community

WHERE	<u>HOW</u>	<u>WHO</u>
 PCP office—birth cohort Hospital—ED/inpatient Prenatal Substance use treatment programs/services Outreach—homeless shelters, supervised injection sites 	 Current—Ab then RNA Point-of-care—Ab+ then RNA Dried blood spot—Ab with reflex RNA Rapid diagnostic test—RNA 	 PCP—GP/RN/other medical team members ED/hospital staff Peer workers Substance use counselors Outreach workers/case managers

All inter-related—the how will depend on the who and the where







Substance use programs are uniquely well-suited for HCV care

Where

- PCP office—birth cohort
- Hospital—ED/inpatient
- Prenatal
- Substance use treatment programs/services
- Outreach—homeless shelters, supervised injection sites


Addiction services

- High-risk clients
- Needle exchange
- MAT program (methadone, buprenorphine, etc.)
- Harm reduction and outreach
- Supportive housing
- Daily drop-in center
- Peer counselors: can be trained to offer HCV screening and counseling





Linkage: non-specialists can effectively treat HCV



The Kirby Institute. Monitoring hepatitis C treatment uptake in Australia (Issue 7). Available at: https://kirby.unsw.edu.au/report/monitoring-hepatitis-c-treatmentuptake-australia-issue-7-july-2017





OKAY, I GET IT: so who can be treated?

EVERYONE!

- Only clinical reason to consider no treatment is anticipated short life-expectancy
- Pre-treatment assessment can be done in 1-2 outpatient visits (will need complete labs, imaging, counseling)
- "Recent or active injection drug use should <u>not</u> be seen as an absolute contraindication to HCV therapy"... "Scaling up HCV treatment among people who inject drugs is necessary to positively impact the HCV epidemic in the U.S. and globally."
- Cost of HCV therapies have unfortunately led to some payer restrictions: state-by-state criteria, medication formularies





Breakdowns in Care Cascade: historical exclusions for HCV therapy

- Active PWID
- Homelessness
- Alcohol use
- Adherence concerns
- Advanced liver disease (or not advanced enough!)
- Mental health diagnoses (interferon)
- Autoimmune disease (interferon)
- Complex cardiopulmonary disease (ribavirin)

Populations with high HCV prevalence and variable access to healthcare:

Individuals who are incarcerated

People living with HCV/HIV coinfection

Men who have sex with men

Emigrants

Persons who use drugs








2017 NVHR update: drug/alcohol use leads to reduced treatment access in some settings

2017 Medicaid Fee For Service Sobriety Restrictions for HCV Treatment










Why are the newer HCV therapies so great?

- More effective: >90% "cure" rates monitoring much simpler
- Many can treat multiple types/strains of HCV ("pangenotypic")
- Shorter duration of treatment: most 8-12wks
- Fewer pills
- Fewer side effects
- Better options for populations who have been harder to treat in the past (cirrhosis, HIV/HBV co-infection, kidney disease, prior treatment failure)



How do I know when I'm cured?

Sustained Virologic Response 12 with 12-Week Treatment Course










We are making some progress in closing the gaps!









HCV elimination: simplifying and streamlining care

Diagnosis


- Point-of-care testing
- Reflex testing (antibody positive → HCV RNA testing)
- HCV Ag (screening and confirmation in one)

Treatment Evaluation

- No genotype testing needed with pangenotypic regimens
- Simple tools to evaluate for cirrhosis
- APRI/FIB4, elastography
- 1 daily dose (1 pill/day) for 8-12 wks
- No ribavirin, no drug interactions

Treatment

- On-treatment monitoring much simpler
- Affordable







So what can you do?

EDUCATION

LINKAGE TO CARE

HCV

OUTREACH

HEALTH
COACHING



Translating "doctor talk"

Medical term

"Antibody"

"HCV RNA test"

"Genotype"

"Cirrhosis"

"Immunization"

"Sustained Virologic Response" (SVR)

Patient-friendly language

What the immune system makes to fight HCV

Level of hepatitis C virus in the body

Type of hepatitis C virus someone has

Liver scarring/damage

Shot/vaccine


No HCV virus in the body (cured!)





Supporting someone before, during, and after treatment


- Encourage clients to have open communication with medical providers
- Questions to consider: Am I ready (physically/emotionally/ mentally)?
- Everything in place/coordinated with provider?
 - Working number, secure address for medication delivery
 - Destabilizing life events in near future (move/work/school/family)?
 - Responsibilities that might impact engagement and adherence?





Supporting someone before, during, and after treatment

- Friends/family close by to support through and after treatment?
- HCV patient support group in area?
- Adherence
 - Does client believe treatment can work? Do they trust their provider? Do they have support systems who can help remind them about taking medications, keeping appointments?
 - Plan ahead: troubleshoot with client- what is plan if side effects?





What if my client isn't ready for treatment?

- Continue encouraging them to think about it
- Help ensure they remain engaged with HCV team/provider
- Encourage prevention, including hepatitis A, B vaccinations
- Reminders for regular liver cancer screening, if necessary*
- Healthy diet, avoiding liver toxins (including alcohol and some supplements), exercise, rest
- Stress management
- Encourage engagement in HIV, HBV care (if applicable)





Provide

Refer

Coordinate


Motivational interviewing/troubleshooting strategies

Barriers	Examples	Possible Solutions
Socioeconomics	 No insurance or limited coverage Unable to afford medication Difficulty completing forms & follow-up Low literacy level Other examples? 	
Logistical Issues	 Difficulty arranging or having access to reliable transportation Scheduling conflicts & difficulty making appointment on time Difficulty finding child or elder care Other examples? 	
Language & Culture	 Difficulty understanding medical staff & terminology Difficulty speaking or reading English Difficulty communicating desires, needs & concerns Beliefs regarding treatment Other examples? 	
Feelings, Emotions & Mental Health	 Afraid of diagnosis Anxiety about treatment Mistrust or fear Fatalistic feelings about illness Stress Depression Other examples? 	
The Healthcare System	 Difficulty navigating system Difficulty obtaining care when needed Communication gaps Lack of coordination Lack of cultural competency Other examples? 	




Life after cure...

- Staying healthy
- Preventing reinfection
 - o Virus can remain in water, filters, syringes, cookers, for 2-8+ weeks
 - Virus can also remain on straws/pipes
 - Safer sex practices
 - Tattoo equipment should be sterilized
 - Don't share razors/toothbrushes/nail clippers





https://www.cdc.gov/hepatitis/partners/hepatitiscoordslist.htm





Key take-home points

- "Baby boomers" and PWID are two important populations that need increased HCV screening
- Improved screening and broader access to HCV treatment can close gaps in the HCV Care Cascade
- Substance use and mental health co-morbidities are <u>not</u> absolute contraindications for HCV treatment
- HCV elimination is only possible with engagement, linkage, and treatment of more challenging populations





SAMHSA-HRSA Center for Integrated Health Solutions

WHO WE ARE

The SAMHSA-HRSA Center for Integrated Health Solutions (CIHS) is a national training and technical assistance center dedicated to the planning and development of integration of primary and behavioral health care for those with mental illness and/or substance use disorders and physical health conditions, whether seen in specialty mental health or primary care safety-net provider Settings across the country.

CIHS is jointly funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) and the Health Resources Services Administration (HRSA), and is run by the National Council for Behavioral Health, the unifying voice of America's healthcare organizations that deliver mental health and addictions treatment and services.





CIHS News and Resources

Visit

<u>www.integration.samhsa.gov</u>

or e-mail

integration@thenationalcouncil.org

Free consultation on any integration-related topic!





AETC Clinician Consultation Center

The Clinician Consultation Center is a free telephone advice service for clinicians by clinicians. Receive expert clinical advice on HIV, PrEP, PEP, hepatitis C, substance use and perinatal HIV.

Go to nccc.ucsf.edu for more information!

HIV/AIDS Warmline 800-933-3413 HIV testing, ART decisions, complications, and co-morbidities

HEPline 844-HEP-INFO HCV screening and testing, monitoring, treatment

Substance Use Warmline 855-300-3595 Substance use evaluation and management, MAT options Perinatal HIV Hotline 888-448-8765
Pregnant women living with HIV or at-risk for HIV & their infants

PrEPlinePre-exposure prophylaxis for persons at risk for HIV

PEPline 888-448-4911
Occupational and non-occupational exposure evaluation and management



Thank You

SAMHSA's mission is to reduce the impact of substance abuse and mental illness on America's communities.

The mission of HRSA is to improve health and achieve health equity through access to quality services, a skilled health workforce, and innovative programs.

Carolyn Chu (Carolyn.Chu@ucsf.edu) or check out: nccc.ucsf.edu

www.hrsa.gov | www.samhsa.gov | integration.samhsa.gov

